Emerging tyrosine kinase inhibitors for head and neck cancer.
about
Clinical relevance of copy number profiling in oral and oropharyngeal squamous cell carcinomaCCI-779 (Temsirolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximabPrognostic and predictive value of EGFR in head and neck squamous cell carcinomaGenetic and epigenetic characterization of the tumors in a patient with a tongue primary tumor, a recurrence and a pharyngoesophageal second primary tumor
P2860
Emerging tyrosine kinase inhibitors for head and neck cancer.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Emerging tyrosine kinase inhibitors for head and neck cancer.
@en
type
label
Emerging tyrosine kinase inhibitors for head and neck cancer.
@en
prefLabel
Emerging tyrosine kinase inhibitors for head and neck cancer.
@en
P2860
P50
P1476
Emerging tyrosine kinase inhibitors for head and neck cancer.
@en
P2860
P304
P356
10.1517/14728214.2013.842976
P407
P577
2013-10-05T00:00:00Z